Biomarkers Of Response To Cyclin D - CDK4/6 Targeted Therapies In Human Cancers
- 技术优势
- Separation of cancer patients in different subgroups based on these biomarkers will allow personalized treatment, which will save time, money and improve treatment efficacy.These markers provide inclusion/exclusion criteria for clinical trials, which will save time, money and increase success rate.
- 技术应用
- Cancer specimens from individual patients can be tested for the alterations in the relevant predictive biomarkers of sensitivity/resistance via several techniques such as SNP arrays, southern blot analysis, RNA sequencing, ELISA, and antibody-based methodology. If alterations were found, these patients can be considered as appropriate or inappropriate candidates to receive CDK-4/6 inhibitor based therapies as a part of their treatment. Clinical trials testing new CDK-4/6 inhibitors may use these sensitivity/resistance biomarkers as inclusion/exclusion criteria to maximize efficacy signal.
- 详细技术说明
- UCLA researchers have identified a list of genetic markers that have not previously been implicated in tumor susceptibility or resistance to CDK-4/6 inhibition.
- *Abstract
-
UCLA researchers have identified 9 genetic response markers that may play a mechanistic role in determining sensitivity or resistance to treatment with the CDK-4/6 and cyclin D inhibitors.
- *IP Issue Date
- Mar 9, 2017
- *Principal Investigation
-
Name: Dylan Conklin
Department:
Name: Richard Finn
Department:
Name: Dennis Slamon
Department:
Name: Erika Von Euw
Department:
- 申请号码
- 20170067116
- 其他
-
State Of Development
- 9 genetic response markers associated with sensitivity or resistance to CDK-4/6 inhibition are identified.
- These biomarkers were analyzed in 12 different cancer types. The candidate biomarkers predictive of sensitivity were sufficiently frequent and associated with sensitivity in 6 of the 12 cancer histologies. The candidate biomarkers predictive of resistance were sufficiently frequent and associated with resistance in 6 of the 12 cancer histologies.
- These biomarkers are in the pre-clinical, experimental phase and need functional validation and validation in clinical cohorts.
Background
Cancer is a leading cause of death worldwide and the number of new cases is expected to rise by 70% in the next 2 decades. Many cancers have a higher chance of cure if detected earlier and treated adequately. Because cancer describes a complex and heterogeneous group of diseases, standardized treatment across all patients has been proved to be ineffective. Instead, personalized medicine has emerged as an important tool in guiding treatment decisions.
Cyclin-dependent kinases (CDK) control cell cycle transition and have long been considered as promising targets for cancer therapies. However to date, several cdk inhibitors have been evaluated in cancer medicine without significant clinical activity. Clinical trials are currently underway with CDK-4/6 inhibitors and most have been designed as “biomarker independent”. As a result, these trials may show little or no efficacy compared to those enriched for patients with genomic biomarkers of susceptibility to CDK-4/6 inhibition.
Related Materials
Additional Technologies by these Inventors
- Early Detection of Colon Cancer
- Differentially Expressed Genes Associated with Her-2/Neu Overexpression
- Her-2/Neu Overexpression Abrogates Growth Inhibitory Pathways
- Frozen Tissue Microarray Technology for Analysis of RNA, DNA, and Proteins
- Methods and Materials for Characterizing and Modulating Interaction between Heregulin and HER3
- An Amplified and Overexpressed Gene in Colorectal Cancers
- Predictive Markers for Dasatinib to Treat Solid Tumors
- Biomarkers Of Response To Inhibition Of Poly-Adp Ribose Polymerase (PARP) In Human Cancers
- Biomarkers Of Response And Synergistic Combinations With ERK Targeted Therapies In Human Cancers
Tech ID/UC Case
27272/2014-522-0
Related Cases
2014-522-0
- 国家/地区
- 美国
